解剖性肺切除与楔形切除相比与IA期(≤2 cm)非小细胞肺癌生存改善相关
基于美国胸外科医师学会数据库2012至2022年32,340例临床IA期(≤2 cm)非小细胞肺癌患者的真实世界分析显示,风险调整后肺叶切除和肺段切除相比楔形切除与总生存和肺癌特异性生存改善相关,肺叶切除与肺段切除之间无生存差异。
要点
- IA期(≤2 cm)非小细胞肺癌中,肺叶切除和肺段切除相比楔形切除与总生存和肺癌特异性生存改善相关。
- 肺叶切除与肺段切除之间未观察到总生存或肺癌特异性生存差异。
- 楔形切除5年总生存66.3%,低于肺叶切除的71.9%和肺段切除的69.6%。
核心结论
- 在常规临床实践中,对于IA期(≤2 cm)非小细胞肺癌,肺叶切除和肺段切除相比楔形切除与总生存和肺癌特异性生存改善相关。
- 这些发现突显了试验疗效与真实世界效果之间可能存在的差距。
研究设计与样本
- 研究为比较 effectiveness 分析,数据来自美国胸外科医师学会普胸外科数据库,纳入2012年至2022年间接受肺切除的临床IA期(≤2 cm)非小细胞肺癌成年患者。
- 通过链接国家死亡指数和联邦医疗保险与医疗补助服务中心住院数据确定长期生存状态;主要终点为总生存,次要终点包括肺癌特异性生存。
- 采用稳定逆概率加权Cox回归处理选择偏倚并得出风险比(HR)及95%置信区间,比较肺叶切除、肺段切除和楔形切除队列。
主要发现
- 共评估32,340例IA期非小细胞肺癌患者,其中肺叶切除19,778例(5年总生存71.9%,10年总生存44.8%),肺段切除4,279例(5年总生存69.6%,10年总生存44.2%),楔形切除8,283例(5年总生存66.3%,10年总生存41.4%)。
- 风险调整后,肺叶切除相比亚肺叶切除与总生存改善相关(HR 0.87,95%CI 0.83-0.92),并与肺癌特异性生存改善相关(HR 0.84,95%CI 0.73-0.97)。
- 肺叶切除相比楔形切除与总生存改善相关(HR 0.84,95%CI 0.80-0.88),并与肺癌特异性生存改善相关(HR 0.72,95%CI 0.56-0.93)。
- 肺段切除相比楔形切除与总生存改善相关(HR 0.88,95%CI 0.81-0.95),并与肺癌特异性生存改善相关(HR 0.77,95%CI 0.66-0.89)。
- 肺叶切除与肺段切除之间未观察到总生存或肺癌特异性生存差异。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Given the uncertain generalizability of recent clinical trial data, a comparative effectiveness analysis evaluating the long-term survival of "real world" patients may clarify the role of lobectomy and sublobar resection (segmentectomy or wedge resection) in the treatment of early stage NSCLC. METHODS: Adult patients undergoing lung resection for clinical stage IA NSCLC (≤2 cm) between 2012 and 2022 were identified from the Society of Thoracic Surgeons General Thoracic Surgery Database. Long-term vital status was determined by linkage to the National Death Index and Centers for Medicare & Medicaid Services inpatient data. The primary end point was overall survival (OS); secondary end points included lung cancer-specific survival (LCSS). Stabilized inverse probability weighted Cox regression was used to account for selection bias and derive hazard ratios (HRs) with 95% confidence intervals comparing the lobectomy, segmentectomy, and wedge resection cohorts. RESULTS: Overall, 32,340 patients with stage IA NSCLC (19,778 lobectomies [OS = 71.9% (5 y), 44.8% (10 y)], 4279 segmentectomies [OS = 69.6%, 44.2%], and 8283 wedge resections [OS = 66.3%, 41.4%]) were evaluated. After risk adjustment, lobectomy was associated with improved OS and LCSS compared with sublobar resection (HR [OS] = 0.87 [0.83-0.92]; HR [LCSS] = 0.84 [0.73-0.97]). Both lobectomy (HR [OS] = 0.84 [0.80-0.88]; HR [LCSS] = 0.72 [0.56-0.93]) and segmentectomy (HR [OS] = 0.88 [0.81-0.95]; HR [LCSS] = 0.77 [0.66-0.89]) were associated with improved survival compared with wedge resection. No differences in OS or LCSS were observed between lobectomy and segmentectomy. CONCLUSION: In routine clinical practice, lobectomy and segmentectomy are associated with improved OS and LCSS compared with wedge resection for stage IA NSCLC (≤2 cm). These findings highlight the potential gap between trial efficacy and real-world effectiveness.
引用
- Seder CW, Chang SC, Towe CW, et al. Anatomic Lung Resection Is Associated With Improved Survival Compared With Wedge Resection for Stage IA (≤2 cm) NSCLC. J Thorac Oncol. 2025. PMID: 40132758. doi:10.1016/j.jtho.2025.03.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。